Skip to search formSkip to main contentSkip to account menu

panobinostat

Known as: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)- 
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Hodgkin lymphoma (HL) relapsing after an autologous hematopoietic cell transplant (HCT) poses a therapeutic challenge. In this… 
2013
2013
Background Multiple myeloma (MM) remains an incurable disease, with a high unmet need for patients (pts) in the relapsed and… 
2012
2012
Abstract 1852 Background: There are limited treatment options for patients (pts) with multiple myeloma (MM) whose disease is… 
2012
2012
Abstract 4048 Background: Proteasome inhibitors (PI) such as bortezomib and carfilzomib (CFZ) have improved the treatment of MM… 
2012
2012
Panobinostat (LBH589) is a novel pan-deacetylase inhibitor that is currently being evaluated in phase III clinical trials for… 
2012
2012
Introduction: Phase 2 single agent trials with lenalidomide and panobinostat in patients with relapsed or refractory HL have… 
2011
2011
Abstract 3976 Background: The outcomes of patients with multiple myeloma (MM) have significantly improved in recent years mainly… 
2011
2011
Abstract 814 Background: Patients with refractory multiple myeloma (MM) have limited treatment options and an extremely poor… 
2010
2010
1115 Background: In vivo experiments have demonstrated synergy when the histone deacetylase (HDAC) inhibitors are combined with… 
2009
2009
Panobinostat is a novel cinnamic hydroxamic acid pan-deacetylase inhibitor able to induce hyperacetylation of lysine residues on…